Bio-Techne Corporation reported its financial results for the quarter and nine months ended March 31, 2025, revealing a net sales increase of 4% to $316.2 million for the quarter and a 6% rise to $902.7 million for the nine-month period compared to the same periods in the previous year. The company's gross margin improved slightly to 67.9% for the quarter and 65.5% for the nine months, up from 67.4% and 66.4%, respectively, in the prior year. However, net earnings decreased significantly to $22.6 million for the quarter, down from $49.1 million, and to $91.1 million for the nine months, compared to $127.5 million in the previous year. The decline in earnings was attributed primarily to a non-recurring arbitration award and restructuring costs.
In terms of operational performance, Bio-Techne's Protein Sciences segment generated $227.7 million in sales for the quarter, reflecting a 6% increase, while the Diagnostics and Spatial Biology segment saw a 2% rise to $89.2 million. The company noted that organic revenue growth was driven by improving conditions in the pharmaceutical market, particularly in the Protein Sciences segment, and broad-based performance in the Diagnostics and Spatial Biology portfolio. The company also reported a 35% increase in selling, general, and administrative expenses for the quarter, largely due to the arbitration award and restructuring-related charges.
The company has made strategic moves, including an investment of $15 million in Spear Bio during the nine months ended March 31, 2025, although no acquisitions were completed during this period. Bio-Techne continues to focus on optimizing its operations and has initiated restructuring actions aimed at recovering operating margins and enhancing its manufacturing footprint. The company expects to incur costs related to these restructuring efforts through fiscal 2026.
As of March 31, 2025, Bio-Techne's cash and cash equivalents totaled $140.7 million, a decrease from $151.8 million as of June 30, 2024. The company has a revolving line of credit with $670 million available, which it plans to utilize for operational needs and capital expenditures. Looking ahead, Bio-Techne anticipates continued growth driven by its core business and strategic investments, while also managing the impacts of foreign currency fluctuations and market conditions on its operations.
About BIO-TECHNE Corp
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.